The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus ...

Moderna (NASDAQ:MRNA) is planning to launch a messenger-RNA-based vaccine for skin cancer as early as next year, Japanese ...

Merck said it will discontinue its coronavirus vaccine program, while continuing its focus on therapies, following poor immune responses from patients in early-stage trials. Merck & Co. (MRK ...

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

In this photo illustration, the Merck & Co., Inc. logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck's vaccine, branded as Ervebo, is recommended by the World Health Organization's (WHO's) Strategic Advisory Group of Experts on Immunization for those at risk of Ebola exposure during outbreaks.

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Merck’s Ebola vaccine offered substantial protection to people vaccinated during the 2018-2020 outbreak in the Democratic Republic of the Congo, with an effectiveness of 84% in those who had ...

Merck’s (NYSE:MRK) human papillomavirus (HPV) vaccine Gardasil 9 has met key efficacy goals in a pivotal late-stage trial involving Japanese males ages 16 to 26 years. The Phase 3 V503-064 trial ...

Other studies show that rVSV-ZEBOV vaccine reduces the risk of death in Ebola patients who were vaccinated before and even after exposure. Merck & Co Inc’s MRK rVSV-ZEBOV vaccine is the only WHO ...